Twist Bioscience
Wolfe Research Begins Coverage of Hologic at Peer Perform, Tempus and Twist Bioscience at Outperform
Analyst Doug Schenkel said that Tempus has a broad and growing menu and Twist Bio has developed a novel DNA synthesis platform. He set $60 price targets for those companies.
Interpace Biosciences, Miroculus, Twist Bioscience Partner to Automate NGS Library Prep in Cancer Dx
The three companies join forces to automate sample preparation for genetic testing of endocrine and GI cancers using digital microfluidics technology.
Abcam to License Phage Library from Twist Bioscience for Antibody Discovery, Diagnostics
The deal "lays the foundations for a long-term collaboration with Abcam to drive new commercial opportunities," Twist CEO Emily Leproust said.
Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Genetic Testing
The partners will design multiple assay kits in an attempt to make genetic testing for rare diseases more accessible to patients.
Twist Bioscience, Biotia Nab FDA EUA for Hybridization-Based NGS SARS-CoV-2 Assay
The hybridization-based test may provide better detection of emerging COVID-19 variants of concern, due to a higher tolerance for probe mismatches than in PCR.